French biotech stock soars 34% after new data on experimental medicine

According to CNBC, shares of French biotech company Abivax surged thirty-four percent after releasing positive data on its experimental drug for bowel disease. The market's strong response reflects investor confidence in the treatment's potential.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton